# Study of ARO-APOC3 in Healthy Volunteers, Hypertriglyceridemic Patients and Patients With Familial Chylomicronemia Syndrome (FCS)

> **NCT03783377** · PHASE1 · COMPLETED · sponsor: **Arrowhead Pharmaceuticals** · enrollment: 112 (actual)

## Conditions studied

- Hypertriglyceridemia
- Familial Chylomicronemia

## Interventions

- **DRUG:** ARO-APOC3
- **DRUG:** sterile normal saline (0.9% NaCl)

## Key facts

- **NCT ID:** NCT03783377
- **Lead sponsor:** Arrowhead Pharmaceuticals
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2019-03-08
- **Primary completion:** 2021-02-11
- **Final completion:** 2021-02-11
- **Target enrollment:** 112 (ACTUAL)
- **Last updated:** 2025-12-24


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03783377

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03783377, "Study of ARO-APOC3 in Healthy Volunteers, Hypertriglyceridemic Patients and Patients With Familial Chylomicronemia Syndrome (FCS)". Retrieved via AI Analytics 2026-06-16 from https://api.ai-analytics.org/clinical/NCT03783377. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*